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Abstract
Muir-Torre syndrome is a genodermatosis
in which multiple internal malignancies are
associated with cutaneous sebaceous tu-
mours and kerato-acanthomas. A 57-year-
old man presented with multiple seba-
ceous tumours, kerato-acanthomas, verru-
cous carcinoma of the nose, renal cell and
transitional cell carcinomas of the left kid-
ney, adenoma of the colon and a positive
family history of colon carcinoma. He was
treated with interferon (IFN-·2a) s.c. 3 ! 106
U three times a week along with 50 mg iso-
tretinoin daily as well as topical isotretinoin
gel. During a follow-up of 29 months, only 1
sebaceous skin tumour developed and was
removed, whereas more than 30 such skin
tumours had been surgically removed dur-
ing the last 3 years. No evidence of internal
tumour development or recurrence was
found. The combination of IFN with reti-
noids seems to be of promise to prevent
tumour development in Muir-Torre syn-
drome.
Copyright © 2000 S. Karger AG, Basel
Since Muir et al. [1] in 1967 published a
case of multiple carcinomas of the bowel and
larynx in association with sebaceous adeno-
ma and kerato-acanthoma, more than 150
patients have been described with a Muir-
Torre syndrome (MTS) [2]. The MTS is an
autosomal-dominant one closely related to
the cancer family syndrome.
In an analysis of 147 published cases of
MTS, 292 visceral cancers were found; about
one half were colorectal carcinomas and
20% involved the genitourinary tract [3].
Both early detection and curative treatment
of the internal malignancies are challenging.
There is no established prophylactic regi-
men. We report on a patient with definite
MTS in whom preventive therapy appeared
successful.
Case Report
A 57-year-old man was admitted to our
hospital in March 1997, with a 12-year histo-
ry of cutaneous and internal tumours.
Twelve cutaneous tumours up to 2 cm in
diameter were removed from 1985 to 1987;
histology reports are not available.
In 1995, another 10 cutaneous tumours
were excised; they showed varying degrees
of sebaceous differentiation or were kerato-
acanthomas. In 1996, 2 carcinomas of the
left kidney (renal cell carcinoma, transitional
cell carcinoma of renal pelvis) led to ne-
phrectomy. Three further cutaneous seba-
ceous tumours were removed.
The family history disclosed that the pa-
tient’s brother died due to a metastatic colon
cancer.
On examination the patient showed mul-
tiple yellowish or skin-coloured facial pa-
pules. On the neck, shoulder and back multi-
ple mostly cystic tumours and livid scars
from surgery were present (fig. 1a, b, 2a). A
subcutaneous tumour on the right upper arm
was enucleated; it was a large cystic sebaceo-
ma. Additionally a verrucous carcinoma of
the nose and a tubular adenoma of the colon
were removed. The verrucous carcinoma re-
vealed epidermal findings resembling a wart,
i.e. compact hyperkeratosis, focal parakera-
tosis and acanthosis. Furthermore, the typi-
cal findings of pleomorphic keratinocytes,
mitotic figures and dyskeratotic cells led to
the diagnosis of a verrucous carcinoma. His-
tologic findings of some of his sebaceous
tumours have already been described by
Rütten et al. [4; case 7]. The routine labora-
tory examinations were normal as were chest
X-ray and double contrast X-ray of the small
intestine. Oesophagogastroduodenoscopy
showed no tumour but an oesophagitis due
to hiatus hernia. Cystoscopy was normal. A
prostatitis was found.
The diagnosis of MTS was established
according to accepted criteria [2, 3]. As an
attempt to prevent further tumour develop-
ment, we prescribed isotretinoin (Roaccu-
tan®) 50 mg/day and interferon ·2a (IFN-
·2a, Roferon®) s.c. 3 ! 106 U three times a
week. Topical isotretinoin gel (Isotrex®)
completed our regimen. The facial sebaceous
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Fig. 1. Clinical presentation of skin manifestations of MTS. a Multi-
ple sebaceous hyperplasias on the forehead. b Sebaceoma.
Fig. 2. MTS – clinical course during treatment with interferon ·2a
and retinoids. a Before treatment, multiple tumours on the back.
b After 3 months of treatment, the tumours had disappeared.
hyperplasias, i.e. a hair follicle and one or
several enlarged sebaceous glands with sharp
circumscription and a symmetric shape as
well as other remaining cutaneous tumours
disappeared after 3 months (fig. 2a, b). We
reduced the daily isotretinoin dosage to 30
mg. Within the next 9 months only 1 cystic
skin tumour developed. There has been no
evidence of further progression including in-
ternal tumour development. The treatment
has been well tolerated with no severe side-
effects noted. Blood and urine examinations
remained normal.
Discussion
MTS is an autosomal-dominant inher-
ited trait with an increased risk of internal
cancer and a wide range of sebaceous neo-
plasms and kerato-acanthomas [1–3]. In our
patient, we have found the deep cystic seba-
ceous tumours which are particularly sugges-
tive of MTS [4, 5].
A striking change in tumour tissues is a
genomic replication error known as microsa-
tellite instability (MSI) caused by alterations
in at least 1 of 4 DNA mismatch repair
genes. MSI has been found frequently in
germline mutations of the mismatch repair
genes hMSH2 and hMLH1. MTS patients
exhibit significantly more mutations in the
hMSH2 gene than in the hMSH1 gene [6–9].
In addition a loss of heterozygosity has been
detected at D2S119, a marker located in the
vicinity of hMSH2. Proliferating cystic seba-
ceous tumours show a frameshift mutation
in exon 2 of the DNA mismatch repair gene
hMLH1(150insT) [4, 8]. Patients with MSI
form a subgroup of MTS with early onset of
colorectal cancer, prolonged survival follow-
ing diagnosis of visceral malignancy and a
greater number of visceral and skin tumours
[6, 7, 9–11].
The case presented here fulfilled the ac-
cepted criteria for a diagnosis of MTS. He
had numerous sebaceous skin tumours, kera-
to-acanthomas, adenoma of the colon, geni-
tourinary cancer, verrucous cancer of the
nose and a positive family history for colo-
rectal cancer. From the clinical presentation
this case is exceptional since two different
tumours were found in his left kidney – a
renal cell carcinoma and a transitional cell
carcinoma [1–3]. In a recent survey on 205
patients with MTS only 12 had tumours of
the kidney (1 hypernephroma, 11 renal pel-
vis tumours) [12].
While once a tumour is identified, it
must be treated by standard methods, usual-
ly surgical ones, the clinical challenge is pro-
phylaxis. The most rational target for cancer
prevention is minimal cellular deviations
a
b
a
b
Muir-Torre Syndrome Dermatology 2000;200:331–333 333
seen in early phases of carcinogenesis. IFNs
are useful candidates for prophylaxis after
surgical or radiosurgical removal of malig-
nant tumours. IFN-· is widely used in adju-
vant therapy protocols in melanoma, non-
melanoma skin cancer and urogenital cancer
among others. The mechanisms may involve
the induction of apoptosis, as well as anti-
proliferative and immunomodulating effects
[13]. Preclinical and clinical studies suggest
synergistic antiproliferative and differentiat-
ing effects in selected solid tumours [14].
Retinoids have occasionally helped in se-
baceous proliferations and tumours and in
multiple kerato-acanthomas. Isotretinoin
has also been used in some patients with the
MTS [15–17]. Retinoids have been shown to
induce apoptosis in several cell types [18].
During the combined treatment with iso-
tretinoin, IFN-·2a and topical isotretinoin
gel, only 1 cystic skin tumour developed dur-
ing 29 months (after 9 months). There has
been no evidence of new internal tumour
development. The treatment has been well
tolerated without severe side-effects.
Our conclusions are preliminary. How-
ever, the obvious improvement of pre-exist-
ing skin tumours and the prophylaxis of
skin tumour development during combined
treatment with IFN-·2a and isotretinoin is
remarkable. Further studies including pro-
spective trials will show whether the effect is
long lasting and helps prevent internal carci-
nomas.
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